Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

RXI is going to present the following Friday July 12th for their own Analyst and investor Symposium. YOu can imagine all the big shot analysts will be there Roth, JPmorgan, etc. They will post multi dose results of RXI-109 which should be way better than single dose. Since we saw the slide that showed the results to be dose dependent.

They will also talk about the phase 2 trial design, and other early applications like Wet AMD, Dry AMD, PVR, Retinoblastoma, ALS (lou Gherrigs disease), and liver fibrosis. here is the press release:

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-investor-analyst-110200206.html

I would have to say this is my favorite line of the news release: " In addition the company will also give an update on its other earlier stage programs, with special emphasis on the ophthalmologic applications of its game changing self delivering RNAi platform."

Notice how the press release states game changing self delivering RNAi. This is a huge breakthrough for RNAi, other companies have to use nanoparticles, encapsulation, lipids etc. RNAi from RXII is self delivering. No delivery vehicle required!